Industry News
Biotechnology Industry News
Neurology biotech Voyager…
Neurology biotech Voyager Therapeutics has laid off 30 employees, a spokesperson for the Massachusetts-based company confirmed to Fierce Biotech.
After a late-stage miss for…
After a late-stage miss for Vistagen's prospective social anxiety disorder treatment fasedienol, the company's chances at an FDA approval in the indication are looking slimmer.
The former director of the…
The former director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases is suing Trump administration officials over her September firing, which she alleges violated her rights and was illegal under
Norgine secured an exclusive…
Norgine secured an exclusive license to commercialize Vir Biotechnology's combo hepatitis D prospect of tobevibart and elebsiran in Europe, Australia and New Zealand.
After layoffs this fall, Mythic…
After layoffs this fall, Mythic Therapeutics is winding down, while asthma-focused Areteia Therapeutics is reportedly shuttering mere months after reporting a phase 3 win for its oral biologic.
Bristol Myers Squibb has become…
Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour BioMed for a multiyear research deal.
University of California spinout…
University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will fuel a new wave of genetic medicine.
Nektar Therapeutics is planning to…
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia areata, even after the asset narrowly missed the main goal of a midstage trial.
Vivek Ramaswamy has found time out…
Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech. The new firm, Ambros Therapeutics, launched Tuesday with a $125 million series A and plans to develop
The FDA has delayed an approval…
The FDA has delayed an approval decision for Aldeyra Therapeutics’ lead dry eye disease candidate, adding another detour to the candidate’s winding road to potentially reach the market.
U.S.-based Yarrow Bioscience is…
U.S.-based Yarrow Bioscience is branching out, picking an autoimmune thyroid disease drug from China as its lead candidate.
A flurry of deal-making hasn’t…
A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris Life Sciences.
Xoma, which styles itself as a…
Xoma, which styles itself as a “biotech royalty aggregator,” has struck a deal to acquire Generation Bio for roughly $4.29 per share at the time of the planned merger’s close.
Sanofi is back with its second…
Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease.
MapLight Therapeutics is the…
MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. The neuro-focused company is penning a strategic collaboration meant to develop new therapies for central nervous system diseases.
Aviceda Therapeutics has hit a…
Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy, an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay
Cell therapy company Link Cell…
Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue.
Seattle’s Adaptive…
Seattle’s Adaptive Biotechnologies is linking up with Pfizer on two non-exclusive pacts that leverage the biotech’s bespoke T-cell receptor discovery engine and large-scale immune receptor antigen-mapping data. At the same time, Dren Bio said it
AI drug developer Chai Discovery…
AI drug developer Chai Discovery has brewed up a $130 million series B to juice its development of a “computer-aided design suite” for new therapeutics.
Immunome’s investigational oral…
Immunome’s investigational oral therapy slashed the risk of disease progression or death by 84% for patients with desmoid tumors, data one analyst is deeming a “near best-case outcome.”